Literature DB >> 21715433

The mislabelling of deoxycorticosterone: making sense of corticosteroid structure and function.

Gavin P Vinson1.   

Abstract

Over the 70 or so years since their discovery, there has been continuous interest and activity in the field of corticosteroid functions. However, despite major advances in the characterisation of receptors and coregulators, in some ways we still lack clear insight into the mechanism of receptor activation, and, in particular, the relationship between steroid hormone structure and function remains obscure. Thus, why should deoxycorticosterone (DOC) reportedly be a weak mineralocorticoid, while the addition of an 11β-hydroxyl group produces glucocorticoid activity, yet further hydroxylation at C18 leads to the most potent mineralocorticoid, aldosterone? This review aims to show that the field has been confused by the misreading of the earlier literature and that DOC, far from being relatively inactive, in fact has a wide range of activities not shared by the other corticoids. In contrast to the accepted view, the presence of an 11β-hydroxyl group yields, in corticosterone or cortisol, hormones with more limited functions, and also more readily regulated, by 11β-hydroxysteroid dehydrogenase. This interpretation leads to a more systematic understanding of structure-function relationships in the corticosteroids and may assist more rational drug design.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715433     DOI: 10.1530/JOE-11-0178

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  11 in total

Review 1.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

Review 2.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 3.  Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?

Authors:  Elise P Gomez-Sanchez
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

4.  Adrenal steroid hormones and ethanol self-administration in male rhesus macaques.

Authors:  Christa M Helms; Byung Park; Kathleen A Grant
Journal:  Psychopharmacology (Berl)       Date:  2014-05-01       Impact factor: 4.530

5.  MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction.

Authors:  Maryam Syed; Jana P Ball; Keisa W Mathis; Michael E Hall; Michael J Ryan; Marc E Rothenberg; Licy L Yanes Cardozo; Damian G Romero
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-28       Impact factor: 4.310

6.  Mineralocorticoid Receptor (MR) trans-Activation of Inflammatory AP-1 Signaling: DEPENDENCE ON DNA SEQUENCE, MR CONFORMATION, AND AP-1 FAMILY MEMBER EXPRESSION.

Authors:  Edward J Dougherty; Jason M Elinoff; Gabriela A Ferreyra; Angela Hou; Rongman Cai; Junfeng Sun; Kevin P Blaine; Shuibang Wang; Robert L Danner
Journal:  J Biol Chem       Date:  2016-09-20       Impact factor: 5.157

Review 7.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

8.  Lesion of the OVLT markedly attenuates chronic DOCA-salt hypertension in rats.

Authors:  John P Collister; David B Nahey; Rochelle Hartson; Charles E Wiedmeyer; Christopher T Banek; John W Osborn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-06-13       Impact factor: 3.619

9.  Addiction and the adrenal cortex.

Authors:  Gavin P Vinson; Caroline H Brennan
Journal:  Endocr Connect       Date:  2013-05-31       Impact factor: 3.335

10.  Mineralocorticoid hypertension and hypokalaemia induced by posaconazole.

Authors:  Charlotte Boughton; David Taylor; Lea Ghataore; Norman Taylor; Benjamin C Whitelaw
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.